$EVOK
Evoke Pharma Inc

2020 Q1 Form 10-Q Financial Statement

#000156459020024523 Filed on May 12, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.330M $1.220M
YoY Change 9.0% 18.45%
% of Gross Profit
Research & Development $463.9K $746.9K
YoY Change -37.89% -46.09%
% of Gross Profit
Depreciation & Amortization
YoY Change
% of Gross Profit
Operating Expenses $1.794M $746.9K
YoY Change 140.16% -69.11%
Operating Profit -$1.794M
YoY Change
Interest Expense $3.378K $0.00
YoY Change -100.0%
% of Operating Profit
Other Income/Expense, Net $3.378K $0.00
YoY Change -100.0%
Pretax Income -$1.790M -$1.970M
YoY Change -9.14% -0.51%
Income Tax
% Of Pretax Income
Net Earnings -$1.790M -$1.965M
YoY Change -8.9% -0.88%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$73.24K -$112.7K
COMMON SHARES
Basic Shares Outstanding 17.43M
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $4.130M $4.030M
YoY Change 2.48% -25.51%
Cash & Equivalents $4.133M $4.029M
Short-Term Investments
Other Short-Term Assets $400.0K $11.55K
YoY Change 3362.9% -93.58%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $4.530M $4.260M
YoY Change 6.34% -23.66%
LONG-TERM ASSETS
Property, Plant & Equipment $110.0K $100.0K
YoY Change 10.0%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $0.00 $0.00
YoY Change
Total Long-Term Assets $110.0K $100.0K
YoY Change 10.0%
TOTAL ASSETS
Total Short-Term Assets $4.530M $4.260M
Total Long-Term Assets $110.0K $100.0K
Total Assets $4.640M $4.360M
YoY Change 6.42% -21.86%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $930.0K $490.0K
YoY Change 89.8% -10.91%
Accrued Expenses $790.0K $800.0K
YoY Change -1.25% 23.08%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $1.716M $1.290M
YoY Change 33.04% 7.9%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities
YoY Change
Total Long-Term Liabilities $0.00 $0.00
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities $1.716M $1.290M
Total Long-Term Liabilities $0.00 $0.00
Total Liabilities $1.720M $1.290M
YoY Change 33.33% 7.9%
SHAREHOLDERS EQUITY
Retained Earnings -$87.52M
YoY Change
Common Stock $90.44M
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $2.922M $3.075M
YoY Change
Total Liabilities & Shareholders Equity $4.638M $4.360M
YoY Change 6.37% -21.93%

Cashflow Statement

Concept 2020 Q1 2019 Q1
OPERATING ACTIVITIES
Net Income -$1.790M -$1.965M
YoY Change -8.9% -0.88%
Depreciation, Depletion And Amortization
YoY Change
Cash From Operating Activities -$1.552M -$1.927M
YoY Change -19.46% -31.62%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $21.25K $636.4K
YoY Change -96.66% 16.85%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 21.25K 636.4K
YoY Change -96.66% 16.85%
NET CHANGE
Cash From Operating Activities -1.552M -1.927M
Cash From Investing Activities
Cash From Financing Activities 21.25K 636.4K
Net Change In Cash -1.531M -1.290M
YoY Change 18.61% -43.23%
FREE CASH FLOW
Cash From Operating Activities -$1.552M -$1.927M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
138538
CY2019Q4 us-gaap Assets
Assets
6395628
CY2019Q4 us-gaap Accounts Payable And Accrued Liabilities Current
AccountsPayableAndAccruedLiabilitiesCurrent
1033383
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
843162
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
138538
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
11551
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
105352
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
1716246
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
2015083
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
2446
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
2443
CY2020Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
90439901
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
90108492
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
378959
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-87520699
CY2018Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5319004
CY2019Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4028550
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-85730390
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
2921648
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
4380545
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
4637894
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
6395628
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
17484318
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
21250
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
4025320
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
3075445
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
310162
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
378959
CY2020Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-227089
CY2019Q1 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-142299
CY2020Q1 evok Increase Decrease In Accounts Payable And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndOtherCurrentLiabilities
-298837
CY2019Q1 evok Increase Decrease In Accounts Payable And Other Current Liabilities
IncreaseDecreaseInAccountsPayableAndOtherCurrentLiabilities
-482878
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1551895
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-1926886
CY2020Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
21250
CY2019Q1 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
636432
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21250
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
636432
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1530645
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-1290454
CY2020Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:6pt;margin-top:6pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ materially from those estimates. </p>
CY2020Q1 evok Entity Incorporation Month And Year Of Incorporation
EntityIncorporationMonthAndYearOfIncorporation
2007-01
CY2007Q2 us-gaap Research And Development In Process
ResearchAndDevelopmentInProcess
650000
CY2020Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
2200000
CY2020Q1 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y3M14D

Files In Submission

Name View Source Status
0001564590-20-024523-index-headers.html Edgar Link pending
0001564590-20-024523-index.html Edgar Link pending
0001564590-20-024523.txt Edgar Link pending
0001564590-20-024523-xbrl.zip Edgar Link pending
evok-10q_20200331.htm Edgar Link pending
evok-20200331.xml Edgar Link completed
evok-20200331.xsd Edgar Link pending
evok-20200331_cal.xml Edgar Link unprocessable
evok-20200331_def.xml Edgar Link unprocessable
evok-20200331_lab.xml Edgar Link unprocessable
evok-20200331_pre.xml Edgar Link unprocessable
evok-ex101_205.htm Edgar Link pending
evok-ex102_206.htm Edgar Link pending
evok-ex103_204.htm Edgar Link pending
evok-ex311_10.htm Edgar Link pending
evok-ex312_8.htm Edgar Link pending
evok-ex321_6.htm Edgar Link pending
evok-ex322_9.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R3.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending